Accessibility Menu
Avicanna logo

Avicanna(TSX) AVCN

Market CapCA$15.72MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-98%
5 Year-88%
1 Year-55%
1 Month+0%
CA$0.13
+0.00%
+0.00Today
Avicanna last closing stock price
MetricPriceDate
Last closeCAD 0.132026-07-31
Avicanna stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-7.41%CAD 0.142026-07-24
1 month+0%CAD 0.132026-06-30
3 month-13.79%CAD 0.152026-05-01
Year to date-44.44%CAD 0.232025-12-30
1 year-55.36%CAD 0.282025-07-31
3 year-59.68%CAD 0.312023-08-01
5 year-88.43%CAD 1.082021-06-11
Since inception-97.99%CAD 6.232019-07-18

Avicanna Financials at a Glance

Market Cap

CA$15.72MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$25.83M

Net Income (TTM)

-CA$3.59M

EPS (TTM)

-CA$0.03

P/E Ratio

-3.98

Dividend

CA$0.00

Beta (Volatility)

1.03 (Average)

Price

CA$0.13

Volume

27,657

Open

CA$0.13

Previous Close

CA$0.13

Daily Range

CA$0.13 - CA$0.13

52-Week Range

CA$0.10 - CA$0.30

Estimated Earnings Date

Aug 12, 2026

AVCN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Avicanna

Avicanna Inc. is a biopharmaceutical company based in Toronto, Canada, focused on the research, development, and commercialization of scientifically validated cannabinoid-based products for medical and consumer health markets. Founded in 2016, the company has established a comprehensive scientific framework that includes R&D and clinical trials, often in collaboration with academic and medical institutions.

Products and Services
  • Medical and wellness products under the RHO Phyto brand
  • CBD-infused topical and derma-cosmetic products marketed under Pura H&W and Pura Earth
  • Bulk cannabis and hemp-derived raw materials through the Aureus brand
Growth Outlook
  • Recent quarterly revenue reached CAD 6.68 million, indicating strong market demand
  • Expansion of product lines is expected to drive future revenue growth
  • Partnerships with academic institutions enhance research capabilities and product development
Financial Highlights
  • Trailing twelve months (TTM) revenue of CAD 25.5 million reflects consistent sales growth
  • Gross profit margin of 51.3% demonstrates effective cost management
  • Operating expenses have been strategically managed, with a focus on R&D investments
Avicanna Inc. is positioned in a rapidly growing industry, leveraging its scientific expertise to develop innovative cannabinoid-based therapies. The company's diverse product offerings and strategic partnerships provide a solid foundation for future growth. Recent financial performance indicates a positive trajectory, with increasing revenue and a strong gross profit margin. As the market for cannabinoid products continues to expand, Avicanna's commitment to research and development may enhance its competitive advantage and drive long-term success.
AI Generated • Jul 17, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

112

CEO

Aras Azadian, MBA

Website

www.avicanna.com

Headquarters

Toronto, ON M5G 1V2, CA

AVCN Financials

Key Financial Metrics (TTM)

Gross Margin

51.34%

Operating Margin

-12.95%

Net Income Margin

-13.90%

Return on Equity

-116.09%

Return on Capital

-95.51%

Return on Assets

-16.26%

Earnings Yield

-25.13%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

CA$15.72MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

125.79M

Volume

27.66K

Avg. Volume

186.19K

Financials (TTM)

Gross Profit

CA$13.26M

Operating Income

-CA$3.35M

EBITDA

-CA$2.63M

Operating Cash Flow

-CA$2.12M

Capital Expenditure

-CA$128.83K

Free Cash Flow

-CA$2.25M

Cash & ST Invst.

CA$372.10K

Total Debt

CA$0.00

Avicanna Performance Analysis

Avicanna annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CAD 4,047,88123.8%
20232023-12-31CAD 16,791,483314.8%
20242024-12-31CAD 25,459,21551.6%
20252025-12-31CAD 25,478,6950.1%
Avicanna sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-2.6%
Q32025-09-303.9%
Q42025-12-313.2%
Q12026-03-311.2%
Avicanna annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CAD -0.23-44.2%
20232023-12-31CAD -0.09-59.0%
20242024-12-31CAD -0.04-57.1%
20252025-12-31CAD -0.02-37.8%
Avicanna sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-1000.0%
Q32025-09-30-84.1%
Q42025-12-3132.8%
Q12026-03-3137.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

CA$6.68M

+5.6%

Gross Profit

CA$3.49M

-3.1%

Gross Margin

52.29%

N/A

Market Cap

CA$15.72MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

CA$140.39K

N/A

Employees

112

N/A

Net Income

-CA$581.64K

-878.4%

EBITDA

-CA$323.72K

-208.1%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

CA$372.10K

-18.5%

Total Debt

CA$0.00

-100.0%

Accounts Receivable

CA$3.47M

+46.2%

Inventory

CA$4.09M

-5.9%

Long Term Debt

CA$0.00

N/A

Short Term Debt

CA$0.00

-100.0%

Return on Assets

-16.26%

N/A

Return on Invested Capital

-25.02%

N/A

Free Cash Flow

-CA$969.35K

-514.6%

Operating Cash Flow

-CA$956.36K

-5307.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ROMJ.VRubicon Organics Inc.
CA$0.47+4.44%
LABS.TOMediPharm Labs Corp.
CA$0.08+0.00%
RVX.TOResverlogix Corp.
CA$0.10-5.00%
CWEB.TOCharlotte's Web Holdings, Inc.
CA$0.32+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.36+0.02%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$23.99+0.01%
PLTRPalantir Technologies
$125.65+0.02%
TQQQProShares Trust - ProShares UltraPro Qqq
$67.96+0.05%

Questions About AVCN

What is the current price of Avicanna?

Avicanna is trading at CA$0.13 per share.

What is the 52-week range for Avicanna?

Over the past 52 weeks, Avicanna has traded between CA$0.10 and CA$0.30.

How much debt does Avicanna have?

As of the most recent reporting period, Avicanna reported total debt of CA$0.00.

How much cash does Avicanna have on hand?

Avicanna reported CA$372.10K in cash and cash equivalents in its most recent financial results.

What is Avicanna’s dividend yield?

Avicanna does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services